Pharmaceuticals News and Research

RSS

Octapharma receives FDA approval for octagam to treat disorders of immune system

The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam, the Octapharma USA product used to treat disorders of the immune system.

5 Nov 2011

Global Pharm acquires Qingdao Likang

Global Pharm Holdings Group, Inc., a China-based, growing vertically integrated pharmaceutical company engaged in pharmaceutical-related products distribution, Traditional Chinese Medicine herbs cultivation and processing business through its subsidiaries in Anhui, Jilin, Guangdong and Shandong provinces, today announced that, on October 31, 2011, it completed the acquisition of the 100% equity interest of Qingdao Likang Pharmaceutical Co., Ltd, a city-level pharmaceutical distributor located in Qingdao, Shandong Province.

5 Nov 2011

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm.

5 Nov 2011

Opexa reports net loss of $1.30 million for third quarter 2011

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2011 and provided an overview of recent corporate developments.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Idera raises $9.5M in convertible preferred stock offering

Idera Pharmaceuticals, Inc. today announced it has raised $9.5 million in a convertible preferred stock offering.

5 Nov 2011

'Medicine that grows' confronts antibiotics resistance

It's been called "the trots," "Montezuma's Revenge," "the runs" and worse. But no matter the name, when it strikes, victims wish for a medicine that could go straight to the offending bacteria to quickly knock it dead.

4 Nov 2011

AMAG reports third quarter total revenues of $17.6 million

AMAG Pharmaceuticals, Inc. today reported unaudited consolidated financial results for the third quarter ended September 30, 2011.

4 Nov 2011

Quanticel, Celgene and Versant enter collaboration to discover and develop first-in-class cancer drugs

Privately held biotechnology company Quanticel Pharmaceuticals Inc. and Celgene Corporation, together with Versant Ventures, today announced they have entered into an exclusive, strategic collaboration to discover and develop first-in-class cancer drugs.

4 Nov 2011

Baxter launches NUMETA emulsion for infusion in Europe

Baxter International Inc. announced today the European launch of NUMETA (emulsion for infusion).

From Baxter International Inc. 4 Nov 2011

Vanda third quarter total revenues increase to $8.0 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2011.

4 Nov 2011

Roundup: Mental health hospital woes; N.Y. Medicare scam bust

A Miami Herald series "Neglected to Death," focused this spring on critical breakdowns in Florida's enforcement system, including failures by the state's Agency on Health Care Administration to fully investigate deaths or to shut down some of the worst offenders among Florida's 2,850 assisted-living facilities. Although more states are using Medicaid money to pay for some portion of assisted living care for the poor, the federal government has a limited role in the facilities their oversight has been and will likely continue to be a state duty.

4 Nov 2011

Financial investment, progress in HIV/AIDS treatment must be protected by international patent law

In this Hill opinion piece, John Castellani, CEO and president of the Pharmaceutical Research and Manufacturers of America, writes, "Over the past three decades, more than 30 treatments have been approved to treat HIV/AIDS," but he adds, "While this is remarkable progress, it's not enough."

4 Nov 2011

Pfizer, Sanford-Burnham to partner on translational medicine research

Sanford-Burnham Medical Research Institute is the latest research organization to partner with Pfizer, Inc. as part of Pfizer's commitment to transforming research and development through a focus on translational medicine.

4 Nov 2011

TPI announces formulation expansion program for GMOL

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid.

4 Nov 2011

Final results from Vertex KALYDECO second of two Phase 3 studies on CF

Vertex Pharmaceuticals Incorporated today announced final results from the ENVISION study, the second of two pivotal Phase 3 studies of KALYDECO, a medicine in development that targets the defective protein that causes cystic fibrosis.

4 Nov 2011

Bristol-Myers Squibb, ASLAN partner to develop BMS-777607 for solid tumors

ASLAN Pharmaceuticals Pte Ltd, a pharmaceutical company headquartered in Singapore, and Bristol-Myers Squibb Company today announced an innovative strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb's investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors.

4 Nov 2011

Savient third quarter net loss decreases to $27.4 million

Savient Pharmaceuticals, Inc. reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA (pegloticase). Savient ended the quarter with $202.7 million in cash and short-term investments, a decrease of $37.6 million for the quarter.

3 Nov 2011

The brain and the heart may not be so different after all

What do heart disease and dementia have in common? Perhaps more than meets the eye, according to researchers at the University of Rochester Medical Center.

3 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011